Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-12-03 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-12-03 English
424B3 Filing
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of American Depositary Shares by selling shareholders. It includes detailed information about the offering, risk factors, use of proceeds, dividend policy, capitalization, share descriptions, selling shareholders, and legal matters. The document is not a financial report, earnings release, or management discussion but a registration and offering document for securities resale. This type of document fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes through a securities offering prospectus.
2024-12-03 English
424B3 Filing
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus related to the offering and resale of American Depositary Shares (ADSs) and warrants by a selling shareholder. It includes information about the securities being offered, the selling shareholder, the purchase agreement, risk factors, use of proceeds, dividend policy, capitalization, share capital description, plan of distribution, legal matters, and other related disclosures. The document is filed pursuant to Rule 424(b)(3), which is a prospectus filing related to securities offerings. This type of document is a capital markets filing that provides detailed information about a securities offering, including resale by a selling shareholder, but it is not a financial report, earnings release, or management discussion. It is specifically a prospectus related to capital raising and share issuance activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-12-03 English
POS AM
Regulatory Filings Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form F-1 Registration Statement filed with the SEC, related to the Securities Act of 1933. It updates the registration statement to include audited consolidated financial statements and other information from the company's Annual Report on Form 20-F for the fiscal year ended June 30, 2024. The document is a regulatory filing related to securities registration and amendments, not a financial report like an Annual Report or Earnings Release. It is a formal SEC filing updating a registration statement, which fits the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed legal and regulatory information about securities registration, not a report or presentation of financial results or management commentary. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-11-27 English
POS AM
Regulatory Filings Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form F-1 Registration Statement filed with the SEC, related to the registration of American Depositary Shares (ADSs) for Kazia Therapeutics Limited. It includes updates such as audited consolidated financial statements from the Annual Report on Form 20-F for the fiscal year ended June 30, 2024, and other information to update the registration statement. The document is a regulatory filing related to securities registration and amendments, not a financial report like an Annual Report or Earnings Release. It is a formal SEC filing updating a registration statement, which fits the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but an amendment filing itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-11-27 English
FORM 20-F
Annual Report FY 2024
2024-11-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.